Business Wire

NY-PYRAMID-ANALYTICS

9.5.2022 13:02:12 CEST | Business Wire | Press release

Share
Pyramid Analytics Closes $120 Million Series E Financing

Pyramid Analytics (Pyramid), a pioneering decision intelligence platform provider – next-generation business analytics for the enterprise – announced today that it has closed a Series E funding round of $120 million, bringing the company’s total venture capital raise to more than $200 million. The round was led by H.I.G. Growth Partners , the dedicated growth capital investment affiliate of H.I.G. Capital, a leading global alternative investment firm with over $48 billion of equity capital under management1 , with the participation of Clal Insurance Enterprises Holdings, Kingfisher Capital, and General Oriental Investments. Early investors who participated in this new round are JVP , Maor Investments, Sequoia Capital , and Viola Growth .

Key Points:

  • New capital will finance Pyramid’s continued innovation advantage and hyper growth.
  • Decision intelligence pioneer raised $211 million to date, inclusive of the Series E.
  • Scott Hilleboe , Co-Head, H.I.G. Growth Partners, joins the Pyramid Board of Directors.
  • The Pyramid Decision Intelligence Platform ranked first for Augmented Analytics Use Case in the Gartner Critical Capabilities for Analytics and Business Intelligence Platforms, 2022.
  • Pyramid is on an accelerated path to become the next analytics leader.

The $120 million round will be strategically invested to drive hyper growth and make Pyramid​ the next Analytics Leader by accelerating the company’s first-mover advantage in augmented analytics capabilities and the decision intelligence category. Pyramid will allocate funds to:

  • Continuously innovate the Pyramid Decision Intelligence Platform to best serve the business analytics needs of our customers, continue to define the emerging decision intelligence market, and maintain a technology advantage over legacy business intelligence tools such as Microsoft Power BI, Qlik and Tableau.
  • Expand the company’s global geographic presence, capture a larger share of the Total Addressable Market for analytics, and increase Channel partnerships with complementary technology companies , independent software vendors (ISV), consulting firms, value-added resellers (VAR) and systems integrators (SI).
  • Enhance the Pyramid customer experience with unmatched service and support, learning and professional certification, and networking and community.
  • Become the greatest employer brand in analytics to effectively hire, reward and retain the best talent, including customer success, marketing, sales, and software engineering and development.

Pyramid Backed by Global Investors Shaping the Future of Technology

H.I.G. Growth Partners’ portfolio companies represent leading companies in the SaaS, eCommerce, Healthcare and Technologies industries throughout North America, Europe, and Latin America. Clal Insurance Enterprises Holdings provides insurance and financial services in Israel. Geneva-based General Oriental Investments is the Investment Management arm of the Cavamont / Cavenham Group of Companies which invest worldwide in all asset classes.

Returning investors are JVP, Maor Investments, Sequoia Capital, and Viola Growth. JVP is a visionary venture capital firm that has been instrumental in building some of the world’s largest companies and facilitating 12 IPOs on NASDAQ. These include Qlik, an early entrant in the business intelligence market, launched in the United States by JVP. Viola Growth is a technology growth capital fund, focusing on investing in global companies at the expansion phase. Portfolio companies include Outbrain, Similarweb, and Trigo. Sequoia Capital is a renowned VC firm whose portfolio companies include Okta, Snowflake, and Zoom.

What is Decision Intelligence?

Decision Intelligence is the fast-emerging, next big innovation in analytics which will accelerate data-driven transformation. There is more data available for analytics than ever before. More people are interested in making decisions with data. More sophisticated analytics are in demand.

Decision Intelligence is designed to speed up insights, scale adoption, and simplify analytics. More people want and require access to data to make faster, more intelligent decisions. These include internal and external non-technical stakeholders. Decision Intelligence empowers anyone to make faster, more intelligent decisions. And that can change everything.

Decision Intelligence is the Next Big Analytics Innovation

The next major innovation in analytics is Artificial Intelligence (AI). Applying AI across Data Prep, Business Analytics, and Data Science is what separates Decision Intelligence from traditional business intelligence tools such as Microsoft Power BI, Qlik, and Tableau. AI lowers the skills barrier by automating the highly technical work needed to prepare and analyze data and create and share reports and dashboards.

The Pyramid Decision Intelligence Platform delivers data-driven insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics.

$215.7 Billion Total Addressable Market

Worldwide spending on big data and business analytics (BDA) solutions was forecast to reach $215.7 billion in 2021, an increase of 10.1% over 2020, according to a new update to the Worldwide Big Data and Analytics Spending Guide from International Data Corporation (IDC) . The forecast also shows that BDA spending will gain strength over the next five years as the global economy recovers from the COVID-19 pandemic. The compound annual growth rate (CAGR) for global BDA spending over the 2021-2025 forecast period will be 12.8%.

Analyst Viewpoints

Pyramid’s Decision Intelligence strategy was described as evolutionary in a recent analyst report from 451 Research, part of S&P Global Market Intelligence . Pyramid Analytics Plants a Stake in the Decision Intelligence Ground , authored by Krishna Roy, Senior Research Analyst on the Data, AI & Analytics team at 451 Research, examines Pyramid’s Decision Intelligence Platform in the context of the emerging decision intelligence market which experts see as the next evolution in analytics and business intelligence (ABI).

Gartner ranked Pyramid first for Augmented Analytics in the Gartner Critical Capabilities for Analytics and Business Intelligence Platforms, 2022 . Gartner noted that the Pyramid Decision Intelligence Platform also “scored well across all four use cases” evaluated: Augmented Analytics; Enterprise Analytics; General Analytics; Visual Self-Service Analytics. Twenty (20) companies were evaluated on 12 Critical Capabilities, including Microsoft BI, Qlik, and Tableau.

The Pyramid Decision Intelligence Platform won the Dresner Advisory Services 2021 Technology Innovation Awards in seven of 12 Categories. The Technology Innovation Awards are presented to the top-ranked vendors in 12 Dresner Advisory 2021 Wisdom of Crowds® thematic market reports. The annual thematic studies are based on data collected from end-users and provide a real-world perspective on various technical capabilities related to Dresner’s annual research. Each report examines current deployment trends, user intentions, and industry capabilities.

BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category in its BARC BI & Analytics 22 Report . Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (top 22-33% or top 2 products) in its 6 peer groups in The BI & Analytics Survey 22.

Executive Quote

Omri Kohl , Chief Executive Officer and Co-Founder, Pyramid: “I am gratified and humbled by the confidence some of the world’s best technology investors have exhibited in Pyramid; the technology, company, and people. Overwhelming interest from the venture capital community underscores the importance of the problems we help our customers solve and the innovations we introduced to help enterprises in ways BI tools and legacy analytics could not.

“This milestone is a testament to the intellect and hard work of our employees across the globe, commitment of our partners, and trust and advocacy of our customers. All elements are in place to speed Pyramid down the path to being the next enterprise analytics leader.”

Investor Quotes

Scott Hilleboe, Co-Head, H.I.G. Growth Partners: “H.I.G. partners with industry-leading companies to drive transformative change. Pyramid is a model of transformation. The Pyramid Decision Intelligence Platform upended analytics and business intelligence (ABI) by redefining what’s possible when the power of data insights is available to everyone.

“H.I.G. is excited to partner with Pyramid in their next stage of growth. Pyramid drives exceptional ROI to customers by empowering them to make faster, more intelligent decisions leveraging advanced analytics and data insights. I’m thrilled to join the Board of Directors and to collaborate with an exceptional leadership team who have brought a truly innovative, differentiated technology to market.”

Yoav Tzruya , General Partner, JVP : “As experienced investors in the data and analytics, with proven successes such as Qlik, which was led by JVP’s founder & chairperson, Erel Margalit, from early-stage to post-IPO, we are happy to continue and support Pyramid Analytics.

“Analytics solutions, and especially BI systems, have struggled for more than 2 decades, with the promise on delivering true enterprise-wide decision-support capabilities. Today, such solutions are further crippled, coming up short on the support for diverse and distributed data sources, ever-increasing quantities of data, intuitive user experience, while providing needed enterprise capabilities. Pyramid Analytics is the only solution that brings decision intelligence capabilities for anyone – from C-suite to the front-line – to make faster, more intelligent decisions.”

Haim Sadger , Partner, Sequoia Capital: “Sequoia Capital first invested in Pyramid nearly a decade ago. Over this time, the Pyramid leadership team has turned their vision for giving anyone in an organization the power of data and analytics to make faster, more intelligent decisions into reality. Technology innovations, customer growth, industry analyst recognition and commercial success have followed. We are proud to deepen our partnership, and we look forward to being part of Pyramid’s next stage of growth.”

Sami Totah , General Partner, Viola Growth: “Pyramid Analytics is well on its way to becoming a global leader in the fast-growing decision intelligence category. With 110% net customer retention rate and nearly 2,500 organizations that use Pyramid to speed up insights, scale adoption, and simplify analytics for more than 1 million people, we are truly excited to support its next steps of growth.”

About Pyramid Analytics

Pyramid is a pioneering decision intelligence platform provider. Decision Intelligence is what’s next in analytics. The Pyramid Decision Intelligence Platform delivers insights for anyone to make faster, more intelligent decisions. The Pyramid Platform provides instant access to any data, enables automated governed self-service for any person, and serves any analytics need, from the simple to the sophisticated. By uniquely combining Data Prep, Business Analytics, and Data Science with AI guidance in a single environment, the Pyramid Platform reduces cost and complexity while accelerating growth and innovation. This enables a strategic, organization-wide approach to Business Intelligence and Analytics. More than 1 million decision makers rely on Pyramid to make faster, more intelligent decisions. Schedule a demo .

Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include H.I.G. Growth Partners, Jerusalem Venture Partners (JVP), Sequoia Capital and Viola Growth. Learn more at Pyramid Analytics .

1 Based on total capital commitments managed by H.I.G. Capital and affiliates.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye